Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug:519:60-63.
doi: 10.1016/j.cca.2021.04.006. Epub 2021 Apr 20.

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

Andrea Padoan  1 , Luigi Dall'Olmo  2 , Foscarina Della Rocca  3 , Francesco Barbaro  4 , Chiara Cosma  5 , Daniela Basso  1 , Annamaria Cattelan  4 , Vito Cianci  3 , Mario Plebani  6
Affiliations

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

Andrea Padoan et al. Clin Chim Acta. 2021 Aug.

Abstract

Background: Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.

Methods: 163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.

Results: Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.

Conclusions: Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.

Keywords: Antibody; BNT162b2; COVID-19; Immunoassays; Immunological response; SARS-CoV-2 vaccine; Serology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Immunological responses to the two doses of BNT162b2 mRNA vaccine. A) dot-plots of anti S-RBD antibodies measured at baseline (before) and after 12 days or 28 days from the first dose (the dotted lines represent the two cut-offs, 1 kAU/L for Snibe and 0.8 kAU/L for Roche); B-C) comparative anti S-RBD levels at baseline, t12 and t28 (after 12 and 28 days from the first dose) in COVID-19 infection-naïve and previous-natural infection individuals; D) dot-plots of anti S-RBD antibodies measured at t12 and t28 in COVID-19 infection-naïve and previous-natural infection individuals; E - H) correlation of post-vaccination anti-S levels and age with superimposed the linear regression lines (with 95%CI).
See this image and copyright information in PMC

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., Gruber W.C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. - PMC - PubMed
    1. Barrett J.R., Belij-Rammerstorfer S., Dold C., Ewer K.J., Folegatti P.M., Gilbride C., Halkerston R., Hill J., Jenkin D., Stockdale L., Verheul M.K., Aley P.K., Angus B., Bellamy D., Berrie E., Bibi S., Bittaye M., Carroll M.W., Cavell B., Clutterbuck E.A., Edwards N., Flaxman A., Fuskova M., Gorringe A., Hallis B., Kerridge S., Lawrie A.M., Linder A., Liu X., Madhavan M., Makinson R., Mellors J., Minassian A., Moore M., Mujadidi Y., Plested E., Poulton I., Ramasamy M.N., Robinson H., Rollier C.S., Song R., Snape M.D., Tarrant R., Taylor S., Thomas K.M., Voysey M., Watson M.E.E., Wright D., Douglas A.D., Green C.M., Hill A.V.S., Lambe T., Gilbert S., Pollard A.J. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat. Med. 2021;27:279–288. - PubMed
    1. Anderson E.J., Rouphael N.G., Widge A.T., Jackson L.A., Roberts P.C., Makhene M., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., McDermott A.B., Flach B., Lin B.C., Doria-Rose N.A., O’Dell S., Schmidt S.D., Corbett K.S., Swanson P.A., Padilla M., Neuzil K.M., Bennett H., Leav B., Makowski M., Albert J., Cross K., Edara V.V., Floyd K., Suthar M.S., Martinez D.R., Baric R., Buchanan W., Luke C.J., Phadke V.K., Rostad C.A., Ledgerwood J.E., Graham B.S., Beigel J.H. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 2020;383:2427–2438. - PMC - PubMed
    1. European center for disease prevention and control (ECDC), Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU / EEA and the UK Key findings, (2020) 1–22.
    1. Walsh E.E., Frenck R.W., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., Swanson K.A., Li P., Koury K., Kalina W., Cooper D., Fontes-Garfias C., Shi P.-Y., Türeci Ö., Tompkins K.R., Lyke K.E., Raabe V., Dormitzer P.R., Jansen K.U., Şahin U., Gruber W.C. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 2020;383:2439–2450. - PMC - PubMed